Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

96.74 -0.76 (-0.78%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

3 Profitable Stocks for Long-Term Investors

May 28, 2026

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia...

Via StockStory

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out ↗

May 25, 2026

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody...

Via MarketBeat

INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup ↗

May 23, 2026

Via Chartmill

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build ↗

May 18, 2026

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business,...

Via MarketBeat

Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts ↗

April 28, 2026

Via Chartmill

Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case ↗

April 20, 2026

Via Chartmill

Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals ↗

February 21, 2026

Via Chartmill

2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore

May 07, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

Via StockStory

Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 05, 2026

Incyte’s first quarter results were shaped by strong demand across its commercial portfolio, with growth supported by both new and existing products in hemat...

Via StockStory

Topics Earnings

INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance

April 29, 2026

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 20.9% year on year to $1.27 bi...

Via StockStory

Incyte (INCY) Q1 2026 Earnings Call Transcript ↗

April 28, 2026

Incyte (INCY) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Incyte (INCY) Q2 2025 Earnings Transcript ↗

April 28, 2026

Incyte (INCY) Q2 2025 Earnings Transcript

Via The Motley Fool

Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations

April 28, 2026

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 20.9% year on...

Via StockStory

Incyte Earnings: What To Look For From INCY

April 26, 2026

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy...

Via StockStory

Topics Artificial Intelligence

Incyte (INCY) Q4 2024 Earnings Transcript ↗

April 22, 2026

Incyte (INCY) Q4 2024 Earnings Transcript

Via The Motley Fool

INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗

April 11, 2026

Incyte Corp (INCY) shows strong earnings growth and a positive technical setup, suggesting a potential breakout for momentum investors.

Via Chartmill

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

March 29, 2026

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio...

Via StockStory

Topics Artificial Intelligence

2 Growth Stocks with Explosive Upside and 1 We Avoid

March 23, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds

March 16, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

2 Value Stocks to Consider Right Now and 1 We Ignore

March 13, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?

March 11, 2026

Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% inc...

Via StockStory

Topics Stocks

Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗

March 06, 2026

The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal...

Via Stocktwits

1 Cash-Producing Stock with Exciting Potential and 2 We Avoid

March 04, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

3 S&P 500 Stocks to Target This Week

February 23, 2026

The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market. A few standout companies are thriving thanks to strong fundamentals and sustained competitive...

Via StockStory

Topics Stocks

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Via The Motley Fool

Topics Regulatory Compliance

February 18, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call

February 17, 2026

Incyte’s fourth quarter was met with a negative market reaction, despite the company delivering revenue growth above Wall Street expectations. Management attributed this performance to strong...

Via StockStory

Topics Earnings

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Via Finterra

Topics Economy Intellectual Property

INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow

February 11, 2026

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.